Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes

Breyer-Pfaff, U., Pfandl, B., Nill, K., et al. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.155 · Cited by 88

Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes

Yoshii, K., Kobayashi, K., Tsumuji, M., Tani, M., Shimada, N., & Chiba, K. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00613-5 · Cited by 88

PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19

Yu, B., Chen, G., He, N., Ouyang, D., Chen, X., Liu, Z., & Zhou, H. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1255 · Cited by 88

Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.

Postlind, H., DanielsonA, Lindgren, A., & Andersson, S. H. G. (1998) · PubMed · Cited by 88

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

Shon, J., Yoon, Y.-R., Kim, K., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00005 · Cited by 87

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19

Yu, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114231 · Cited by 87

CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia

Inomata, S., NAGASHIMA, A., Itagaki, F., Homma, M., Nishimura, M., Osaka, Y., OKUYAMA, K., Tanaka, E., Nakamura, T. K., & Kohda, Y. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.020 · Cited by 86

In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone

Kroemer, H. K., Mikus, G., Kronbach, T., Meyer, U., & Eichelbaum, M. F. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.5 · Cited by 86

Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism

Sagar, M., Tybring, G., Dahl, M., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.16515 · Cited by 86

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians*1

Vianna‐Jorge, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.002 · Cited by 86

Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation

Kupfer, A., & Branch, R. A. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.196 · Cited by 86

Pharmacokinetic-Pharmacodynamic Relationships of Oral Hypoglycaemic Agents

Marchetti, P., & Navalesi, R. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916020-00004 · Cited by 86

Inhibition of Cytochrome P450 2D6 Metabolism of Hydrocodone to Hydromorphone Does Not Importantly Affect Abuse Liability

Kaplan, H. L., Busto, U. E., Baylon, G. J., Cheung, S. W., Otton, S. V., Somer, G. R., & Sellers, E. M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36599-1 · Cited by 86

Multiple Dose Pharmacokinetics of a New Once Daily Extended Release Tolterodine Formulation Versus Immediate Release Tolterodine

Olsson, B., & Szamosi, J. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00006 · Cited by 85

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol

Hermida, J., Zarza, J., Alberca, I., Montes, R., López, M. L., Molina, E., & Rocha, E. (2002) · Blood · doi:10.1182/blood.v99.11.4237 · Cited by 85

Induction of Cytochrome P450 2B6 and 3A4 Expression by Phenobarbital and Cyclophosphamide in Cultured Human Liver Slices

Martin, H., Sarsat, J. P., de Waziers, I., Housset, C., Balladur, P., Beaune, P. H., Albaladejo, V., & Lerche-Langrand, C. (2003) · Pharmaceutical Research · doi:10.1023/a:1023234429596 · Cited by 84

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin*

Böttiger, Y., Tybring, G., Götharson, E., & Bertilsson, L. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90116-8 · Cited by 84

Reappraisal of Human CYP Isoforms Involved in Imipramine N-Demethylation and 2-Hydroxylation: A Study Using Microsomes Obtained from Putative Extensive and Poor Metabolizers of S-Mephenytoin and Eleven Recombinant Human CYPs

Koyama, E., Chiba, K., Tani, M., & Ishizaki, T. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36731-x · Cited by 84

STUDIES OF THE METABOLISM OF DAPSONE IN MAN AND EXPERIMENTAL ANIMALS: FORMATION OF N-HYDROXY METABOLITES

Israili, Z. H., Cucinell, S. A., Vaught, J., Davis, E., Lesser, J., & Dayton, P. G. (1973) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29658-6 · Cited by 84

Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and Celecoxib

Brenner, S. S., Herrlinger, C., Dilger, K., Mürdter, T. E., Hofmann, U., Marx, C., & Klotz, U. E. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342030-00003 · Cited by 83

Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.

Olesen, O. V., & Línnet, K. (1997) · PubMed · Cited by 83

A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs.

Leemann, T., Transon, C., Bonnabry, P., & Dayer, P. (1993) · PubMed · Cited by 83

Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.

Knodell, R. G., Dubey, R. K., Wilkinson, G. R., et al. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24109-x · Cited by 82

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes*

Yue, Q., Zhong, Z., Tybring, G., et al. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90069-8 · Cited by 82

In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S‐mephenytoin hydroxylase.

Birkett, D., Rees, D. L. P., Andersson, T., Gonzalez, F. J., Miners, J. O., & Veronese, M. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05707.x · Cited by 81

Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo*

Özdemir, V., Naranjo, C. A., Herrmann, N., Reed, K. L., Sellers, E. M., & KALOW, W. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90037-0 · Cited by 81

Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers

Mellström, B., Säwe, J., Bertilsson, L., & Sjöqvist, F. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.56 · Cited by 81

ACETYLATOR STATUS AND RESPONSE TO PHENELZINE IN DEPRESSED PATIENTS

Johnstone, E., & Marsh, W. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90715-0 · Cited by 80

A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam

Kosaki, K., Tamura, K., Sato, R., Samejima, H., Tanigawara, Y., & Takahashi, T. (2004) · Brain and Development · doi:10.1016/j.braindev.2004.02.010 · Cited by 80

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

Dojo, M., Azuma, T., Saito, T., Ohtani, M., Muramatsu, A., & Kuriyama, M. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80043-8 · Cited by 79

Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea

Oh, K.-T. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keh001 · Cited by 79

Cytochrome P450 polymorphisms are associated with reduced warfarin dose

Freeman, B. D., Zehnbauer, B. A., McGrath, S. D., Borecki, I. B., & Buchman, T. G. (2000) · Surgery · doi:10.1067/msy.2000.107283 · Cited by 78

CYP2D6 Inhibition by Selective Serotonin Reuptake Inhibitors: Analysis of Achievable Steady‐State Plasma Concentrations and the Effect of Ultrarapid Metabolism at CYP2D6

Lam, Y. W. F., Gaedigk, A., Ereshefsky, L., Alfaro, C. L., & Simpson, J. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.12.1001.33603 · Cited by 78

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation*

Ishizaki, T., Chiba, K., Manabe, K., Koyama, E., Hayashi, M., Yasuda, S., Horai, Y., Tomono, Y., Yamato, C., & Toyoki, T. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90193-0 · Cited by 78

Circadian rhythm of rat liver dihydropyrimidine dehydrogenase

Harris, B., Song, R., He, Y., Soong, S.-J., & Diasio, R. B. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90349-8 · Cited by 77

Inhibition by Omeprazole of Proguanil Metabolism: Mechanism of the Interaction In Vitro and Prediction of In Vivo Results from the In Vitro Experiments

Funck‐Brentano, C., Becquemont, L., Leneveu, A., Roux, A., Jaillon, P., & Beaune, P. H. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36460-2 · Cited by 77

Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose

Laizure, S. C., DeVane, C. L., Stewart, J. T., Dommisse, C. S., & Lai, A. A. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.228 · Cited by 77

Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone

Funck‐Brentano, C., Becquemont, L., Kroemer, H. K., Bühl, K., Knebel, N. G., Eichelbaum, M. F., & Jaillon, P. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.26 · Cited by 77

The Clinical Role of Cytochrome P450 Genotypes in Helicobacter Pylori Management

Sapone, A., Vaira, D., Trespidi, S., et al. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07427.x · Cited by 77

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

Roh, H., Chung, J., Oh, D.-Y., et al. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01437.x · Cited by 76

Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes.

Coleman, M. D., Breckenridge, A., & Park, B. K. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03517.x · Cited by 76

Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity

Lindqvist, M., Haglund, S., Almer, S. H., et al. (2004) · Pharmacogenetics · doi:10.1097/00008571-200404000-00006 · Cited by 76

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype

Inaba, T., Mizuno, M., Kawai, K., Yokota, K., Oguma, K., Miyoshi, M., Take, S., Okada, H., & Tsuji, T. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02790.x · Cited by 76

Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype

Dahl, M. L., Bertilsson, L., & Nordin, C. (1996) · Psychopharmacology · doi:10.1007/bf02246640 · Cited by 75

CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects

Soga, Y., Nishimura, F., Ohtsuka, Y., Araki, H., Iwamoto, Y., Naruishi, H., Shiomi, N., KOBAYASHI, Y., Takashiba, S., Shimizu, K., et al. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.07.018 · Cited by 74

Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19*

Donahue, S., Flockhart, D. A., Abernethy, D. R., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90054-0 · Cited by 73

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174

McCrea, J. B., Cribb, A. E., Rushmore, T. H., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70114-1 · Cited by 73

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype*

Tanaka, Μ., Ohkubo, T., Otani, K., Suzuki, A., Kaneko, S., Sugawara, K., Ryokawa, Y., Hakusui, H., Yamamori, S., & Ishizaki, T. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90081-3 · Cited by 72

Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).

Jl, C., Irwin, L. E., Gj, M., et al. (1975) · PubMed · Cited by 72

Identification of the human cytochrome P450 isoforms mediating in vitro N‐dealkylation of perphenazine

Olesen, O. V., & Línnet, K. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00298.x · Cited by 70

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19

Kim, K., Shon, J., Park, J. Y., Yoon, Y., Kim, M., Yun, D., Kim, M., Cha, I., Hyun, M. H., & Shin, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126176 · Cited by 70

Effects of the allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

Mihara, K., SUZUKI, A., Kondo, T., YASUI, N., Furukori, H., Nagashima, U., Otani, K., Kaneko, S., & INOUE, Y. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70108-6 · Cited by 70

Polymorphic hydroxylation of perhexiline maleate in man.

Cooper, R. G., Evans, D. A. P., & Whibley, E. J. (1984) · Journal of Medical Genetics · doi:10.1136/jmg.21.1.27 · Cited by 70

CYP2C19 polymorphism effect on phenobarbitone

Mamiya, K., Hadama, A., Yukawa, E., et al. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050703 · Cited by 69

Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6

Dilger, K., Greiner, B., Fromm, M. F., Hofmann, U., Kroemer, H. K., & Eichelbaum, M. F. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00002 · Cited by 69

Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

Suzuki, A., Otani, K., Mihara, K., et al. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00013 · Cited by 69

Role of Cytochrome P-4502C9 in Irbesartan Oxidation by Human Liver Microsomes

Bourrié, M., Meunier, V., Berger, Y., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15292-0 · Cited by 69

Impact of Stereoselectivity on the Pharmacokinetics and Pharmacodynamics of Antiarrhythmic Drugs

Mehvar, R., Brocks, D., & Vakily, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241080-00001 · Cited by 68

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism

Miyoshi, M., Mizuno, M., Ishiki, K., Nagahara, Y., Maga, T., Torigoe, T., Nasu, J., Okada, H., Yokota, K., Oguma, K., et al. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02526.x · Cited by 68

Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.

Fritz, S., Lindner, W. F., Roots, I., et al. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00306-4 · Cited by 67

Identification of cytochromes P 450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

Ufer, M., Svensson, J. O., Krausz, K. W., et al. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0740-5 · Cited by 67

N -Acetyltransferase 1 and 2 Genotypes Do Not Predict Response Or Toxicity To Treatment With Mesalamine and Sulfasalazine in Patients With Ulcerative Colitis

Ricart, E., Taylor, W. R., Loftus, E. V., O’Kane, D. J., Weinshilboum, R. M., Tremaine, W. J., Harmsen, S. W., Zinsmeister, A. R., & Sandborn, W. J. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04194-1 · Cited by 67

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism

Pous, A. F., Sánchez, J. M., Tarón, M., Martinez‐Balibrea, E., Sánchez, J. J., Manzano, J. L., Vila, M. M., Richardet, M. E., Barnadas, A., Abad, A., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1026251202137 · Cited by 66

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

Dahl, M. L., Ekqvist, B., Widén, J., et al. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb01428.x · Cited by 66

Elevated Serum Aminotransferase Induced by Isoniazid in Relation to Isoniazid Acetylator Phenotype

Yamamoto, T., Suou, T., & Hirayama, C. (1986) · Hepatology · doi:10.1002/hep.1840060223 · Cited by 66

The Effect of Fluoxetine on the Pharmacokinetics and Safety of Risperidone in Psychotic Patients

Bondolfi, G., Eap, C. B., Bertschy, G., ZULLINO, D. F., Vermeulen, A., & Baumann, P. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-25026 · Cited by 65

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism

Línnet, K., & Wiborg, O. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90165-4 · Cited by 65

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy – a decision analysis

Chan, F. W. H., Wong, R. S. M., Cheng, G. Y.-M., & You, J. H. S. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-03-0161 · Cited by 65

Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo

Caraco, Y., Muszkat, M., & Wood, A. J. J. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00005 · Cited by 63

Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N‐demethylation of sertraline in human liver microsomes

Xu, Z., Wang, W., Zhao, X., Huang, S., Zhu, B. Y., He, N., Shu, Y., Liu, Z., & Zhou, H. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00023.x · Cited by 62

Influence of oxidation polymorphism on phenformin kinetics and dynamics

Oates, N. S., Shah, R. R., Idle, J. R., & Smith, R. L. (1983) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1983.257 · Cited by 62

Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver disease

Khaliq, Y., Gallicano, K., Seguin, I., et al. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00238.x · Cited by 62

Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers

Eap, C. B., Bondolfi, G., ZULLINO, D. F., Savary, L., Powell-Golay, K., Kosel, M., & Baumann, P. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00013 · Cited by 62

The Impact of CYP2C19 and CYP2D6 Genotypes on Metabolism of Amitriptyline in Japanese Psychiatric Patients

Shimoda, K., Someya, T., Yokono, A., Morita, S., Hirokane, G., Takahashi, S., & Okawa, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00007 · Cited by 61

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

Schalekamp, T., Oosterhof, M. M., VANMEEGEN, E., VANDERMEER, F., Conemans, J. M. H., Hermans, M. H. A., Meijerman, I., & DEBOER, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.006 · Cited by 61

Acenocoumarol stabilization is delayed in CYP2C9*3 carriers

Schalekamp, T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.017 · Cited by 61

Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects

Yoon, Y. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106128 · Cited by 61

Determination of bleeding risk using genetic markers in patients taking phenprocoumon

Hummers, E., Hess, S., Adham, I. M., Papke, T., Pieske, B. M., & Kochen, M. M. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0580-8 · Cited by 60

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

Roh, H., Kim, C. E., Chung, W., et al. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100372 · Cited by 60

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism

Hokari, K., Sugiyama, T., Kato, M., et al. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01063.x · Cited by 60

A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin

Ishikawa, C., Ozaki, H., Nakajima, T., Ishii, T., Kanai, S., ANJO, S., Shirai, K., & Inoue, I. (2004) · Journal of Human Genetics · doi:10.1007/s10038-004-0188-6 · Cited by 60

CONVERSION OF THE HIV PROTEASE INHIBITOR NELFINAVIR TO A BIOACTIVE METABOLITE BY HUMAN LIVER CYP2C19

Hirani, V., Raucy, J. L., & Lasker, J. M. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001743 · Cited by 60

Effects of felbamate on the pharmacokinetics of phenobarbital

Reidenberg, P., Glue, P., Banfield, C. R., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90244-9 · Cited by 60

Steady-State Plasma Levels of Nortriptyline and Its Hydroxylated Metabolites in Japanese Patients: Impact of CYP2D6 Genotype on the Hydroxylation of Nortriptyline

Morita, S., Shimoda, K., Someya, T., Yoshimura, Y., Kamijima, K., & Kato, N. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00005 · Cited by 60

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.

Pollock, B. G., Mulsant, B. H., Sweet, R. A., Rosen, J., Altieri, L. P., & Perel, J. M. (1995) · PubMed · Cited by 60

Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations

Xie, H., Xu, Z., Ouyang, D., et al. (1997) · Pharmacogenetics · doi:10.1097/00008571-199712000-00009 · Cited by 59

Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin

McGourty, J. C., Silas, J. H., Fleming, J. J., et al. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.195 · Cited by 59

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients

Kuilenburg, A. B. P., van LENTHE, H., Blom, M. J., Mul, E. P. J., & Gennip, A. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690097 · Cited by 57

Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: Interethnic differences in comparison with white subjects

Zhang, Y., Reviriego, J., Lou, Y., et al. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.185 · Cited by 57

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin*

Eap, C. B., Guentert, T. W., Schäublin-Loidl, M., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80010-5 · Cited by 57

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

Kirchheiner, J., Müller, G., Meineke, I., Wernecke, K., Roots, I., & Brockmöller, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088909.24613.92 · Cited by 57

Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam

Bonnabry, P., Leemann, T., & Dayer, P. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/bf00226332 · Cited by 57

Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: Evidence from clinical and pharmacokinetic data

Schwab, M. G., Klotz, U. E., Hofmann, U., Schaeffeler, E., LEODOLTER, A., Malfertheiner, P., & Treiber, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.017 · Cited by 57

Procainamide‐Induced Lupus Erythematosus‐like Syndrome in Relation to Acetylator Phenotype and Plasma Levels of Procainamide

Sonnhag, C., Karlsson, E., & HED, J. (1979) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1979.tb13505.x · Cited by 57

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes

Lee, C. R., Pieper, J. A., Hinderliter, A. L., Blaisdell, J. A., & Goldstein, J. A. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127913 · Cited by 56

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

Fröhlich, M., Hoffmann, M. M., Burhenne, J., Mikus, G., Weiß, J., & Haefeli, W. E. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02159.x · Cited by 56

The potential therapeutic role of the enantiomers and metabolites of mianserin.

Pinder, R. M., & Delft, A. V. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb05875.x · Cited by 56

Effect of moderate or severe liver dysfunction on the pharmacokinetics of γ-hydroxybutyric acid

Ferrara, S. D., Tedeschi, L., Frison, G., Orlando, R., Mazzo, M., Zordan, R., Padrini, R., & Palatini, P. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050113 · Cited by 56

, but not , polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects

Yin, O. Q. P., Tomlinson, B., & Chow, M. S. S. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.006 · Cited by 55

Prevention of Postoperative Nausea and Vomiting with Granisetron and Dolasetron in Relation to CYP2D6 Genotype

Janicki, P. K., Schuler, H. G., Jarzembowski, T. M., et al. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000200364.55798.3f · Cited by 55

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis*

Sica, D. A., Marino, M. R., HAMMETT, J., Ferreira, I., Gehr, T. W. B., & Ford, N. F. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90080-1 · Cited by 55

Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor.

Kassahun, K., McIntosh, I. S., Shou, M., Walsh, D. J., Rodeheffer, C., Slaughter, D. E., Geer, L. A., Halpin, R. A., Agrawal, N. G. B., & Rodrigues, A. D. (2001) · PubMed · Cited by 55

Non‐linear fluvoxamine disposition

Spigset, O., Granberg, K., Hägg, S., Söderström, E., & Dahlqvist, R. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00670.x · Cited by 54

Influence of genotypes on the pharmacokinetics and pharmacodynamics of piroxicam

Perini, J. A., Vianna‐Jorge, R., Brogliato, A. R., & Suarez‐Kurtz, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.014 · Cited by 54

Evidence of Polymorphic CYP2C19 Involvement in the Human Metabolism of N-Desmethylclobazam

Contin, M., Sangiorgi, S., Riva, R., Parmeggiani, A., Albani, F., & Baruzzi, A. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200212000-00009 · Cited by 54

Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2

Yasumori, T., Murayama, N., Yamazoe, Y., et al. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.34 · Cited by 54

Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians*

Skjelbo, E., Mutabingwa, T. K., Bygbjerg, I. C., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80008-7 · Cited by 54

Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.

Aoyama, N., Tanigawara, Y., Kita, T., et al. (1999) · PubMed · Cited by 53

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis

Wadelius, M., Stjernberg, E., Wiholm, B., & Rane, A. (2000) · Pharmacogenetics · doi:10.1097/00008571-200002000-00005 · Cited by 53

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9 * 3 allele

Shimamoto, J., Ieiri, I., Urae, A., Kimura, M., Irie, S., Kubota, T., Chiba, K., Ishizaki, T., Otsubo, K., & Higuchi, S. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050722 · Cited by 53

Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady‐state dose

Sallustio, B. C., Westley, I. S., & Morris, R. G. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01618.x · Cited by 52

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

Berecz, R., de la Rubia, A., Dorado, P., et al. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0576-4 · Cited by 52

In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase

Hamdan-Khalil, R., Allorge, D., Lo‐Guidice, J., Cauffiez, C., Chevalier, D., Spire, C., Houdret, N., Libersa, C., Lhermitte, M., Colombel, J., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.103 · Cited by 52

Phenothiazine drug metabolites: Dopamine D2 receptor, α1-and α2-adrenoceptor binding

Hals, P., Hall, H., & Dahl, S. G. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90793-4 · Cited by 52

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

Roberts, R. L., Mulder, R., Joyce, P. R., et al. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.539 · Cited by 50

Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects

Liu, Z., Cheng, Z., Huang, S., et al. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01402.x · Cited by 49

Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics

Danish University Antidepressant Group (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.99720 · Cited by 49

Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance

Brynne, Svanström, Åberg‐Wistedt, Hallén, & Bertilsson (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00051.x · Cited by 48

Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4.

Kilicarslan, T., Haining, R. L., Rettie, A. E., et al. (2001) · PubMed · Cited by 48

Pharmacological Monitoring of Azathioprine Therapy

Reuther, L. Ø., Sonne, J., E., L. N., et al. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310005082 · Cited by 48

AFRICAN SWINE FEVER VIRUS ANTIBODY NOT FOUND IN AIDS PATIENTS

Colaert, J., Desmyter, J., Goudsmit, J., Clumeck, N., & Terpstra, C. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91927-x · Cited by 48

Effect of Venlafaxine versus Fluoxetine on Metabolism of Dextromethorphan, a CYP2D6 Probe

Amchin, J., Ereshefsky, L., Zarycranski, W., Taylor, K. P., Albano, D., & Klockowski, P. M. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010159 · Cited by 48

Steady State Plasma Levels of the Enantiomers of Trimipramine and of Its Metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-Phenotyped Patients

Eap, C. B., Bender, S., Gastpar, M., et al. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200004000-00012 · Cited by 47

Comparison of (S)‐mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms

Coller, Somogyi, & Bochner (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00005.x · Cited by 46

Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population

Hoskins, J. M., Shenfield, G. M., & Gross, A. S. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00807.x · Cited by 46

The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

Jiang, Z., Shu, Y., Chen, X., Huang, S., Zhu, R., Wang, W., He, N., & Zhou, H. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0445-6 · Cited by 46

Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy

Morinobu, S., Tanaka, T., Kawakatsu, S., Totsuka, S., Koyama, E., CHIBA, K., Ishizaki, T., & Kubota, T. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02593.x · Cited by 45

Systemic Adverse Effects of Ophthalmic β-Blockers

Zanden, J. A. V., Valuck, R. J., Bunch, C. L., et al. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.18464 · Cited by 45

Pharmacogenetics—expectations and reality

Tucker, G. T. (2004) · BMJ · doi:10.1136/bmj.329.7456.4 · Cited by 44

N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus

Kaufmann, G. R., Wenk, M., Taeschner, W., Peterli, B., Gyr, K. E., Meyer, U., & Haefeli, W. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90168-x · Cited by 44

S‐adenosylhomocysteine and the ratio of S‐adenosylmethionine to S‐adenosylhomocysteine are not related to folate, cobalamin and vitamin B6 concentrations

Becker‐Commissaris, A., Smulders, Y. M., Teerlink, T., et al. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2003.01104.x · Cited by 44

The multiple dose pharmacokinetics of proguanil.

Helsby, N. A., Edwards, G., Breckenridge, A., & Ward, S. A. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb04197.x · Cited by 43

Intrinsic Efficacy of Proguanil against Falciparum and Vivax Malaria Independent of the Metabolite Cycloguanil

Kaneko, A., Bergqvist, Y., Takechi, M., Kalkoa, M., Kaneko, O., Kobayakawa, T., Ishizaki, T., & Björkman, A. (1999) · The Journal of Infectious Diseases · doi:10.1086/314683 · Cited by 43

Hemolysis during salicylazosulfapyridine therapy.

van Hees, P. A., Lw, V. E., van Rossum, J. M., & Jh, V. T. (1978) · PubMed · Cited by 43

The Effect of CYP2C19 and CYP2D6 Genotypes on the Metabolism of Clomipramine in Japanese Psychiatric Patients

Yokono, A., Morita, S., Someya, T., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00002 · Cited by 42

Pharmacokinetic Studies of 5‐Fluorouracil after Oral and Intravenous Administration in Man

Almersjö, O., Gustavsson, B., Regårdh, C. G., et al. (1980) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1980.tb02463.x · Cited by 42

Steady-State Plasma Concentrations of Imipramine and Desipramine in Relation to S-Mephenytoin 4'-Hydroxylation Status in Japanese Depressive Patients

Koyama, E., Tanaka, T., Chiba, K., Kawakatsu, S., Morinobu, S., Totsuka, S., & Ishizaki, T. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00003 · Cited by 42

A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone

Nyberg, S., Halldin, C., & Dahl, M. (1995) · Psychopharmacology · doi:10.1007/bf02246302 · Cited by 41

Pharmacokinetics of Phenobarbital During Certain Enhanced Elimination Modalities to Evaluate Their Clinical Efficacy in Management of Drug Overdose

Ebid, A. I. M., & Abdel-Rahman, H. M. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200106000-00005 · Cited by 41

Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS

Wolkenstein, P., Loriot, M., Aractingi, S., Cabelguenne, A., Beaune, P. H., & Chosidow, O. (2000) · Pharmacogenetics · doi:10.1097/00008571-200012000-00007 · Cited by 41

Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.

Koyama, E., Sohn, D., Shin, S. G., et al. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23847-2 · Cited by 41

Azathioprine Pharmacogenetics: The Relationship between 6-Thioguanine Nucleotides and Thiopurine Methyltransferase in Patients after Heart and Kidney Transplantation

Schütz, E., Gummert, J. F., Armstrong, V. W., Mohr, F. W., & Oellerich, M. (1996) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1996.34.3.199 · Cited by 40

Gene Expression for Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Influences Outcome in Epithelial Ovarian Cancer

Fujiwaki, R., Hata, K., Nakayama, K., Fukumoto, M., & Miyazaki, K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3946 · Cited by 39

Stereoselective disposition of hexobarbital and its metabolites

Adedoyin, A. B., Prakash, C., O??Shea, D., et al. (1994) · Pharmacogenetics · doi:10.1097/00008571-199402000-00004 · Cited by 39

Metabolism and Pharmacokinetics of Phenelzine

Robinson, D. S., Cooper, T. B., Jindal, S. P., CORCELLA, J., & LUTZ, T. (1985) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198505060-00005 · Cited by 39

Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long‐term omeprazole treatment

SAGAR, JANCZEWSKA, Ljungdahl, �., Bertilsson, & SEENSALU (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00490.x · Cited by 38

Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

Brøsen, K., Skjelbo, E., & Flachs, H. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb04204.x · Cited by 38

Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: A case report

Bluhm, R. E., Wilkinson, G. R., Shelton, R. C., & Branch, R. A. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.13 · Cited by 38

Role of Human CYP2B6 in S-Mephobarbital N-Demethylation

Kobayashi, K., Abe, S., Nakajima, M., Shimada, N., Tani, M., Chiba, K., & Yamamoto, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14953-7 · Cited by 38

N‐acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients [letter]

Deloménie, C., Grant, D., Mathelier‐Fusade, P., Jacomet, C., Leynadier, F., Jacqz-Aigrain, É., Rozenbaum, W., Krishnamoorthy, R., & Dupret, J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04401.x · Cited by 37

Acetylator Phenotype and Genotype in HIV‐Infected Patients with and without Sulfonamide Hypersensitivity

O’Neil, W. M., MacArthur, R. D., Farrough, M. J., Doll, M. A., Fretland, A. J., Hein, D. W., Crane, L. R., & Svensson, C. K. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00970002042006004 · Cited by 37

Medical complications of cocaine: Possible relationship to low plasma cholinesterase enzyme

Om, A., Ellahham, S. H., Ornato, J. P., Picone, C., Theogaraj, J., Corretjer, G. P., & Vetrovec, G. W. (1993) · American Heart Journal · doi:10.1016/0002-8703(93)90122-p · Cited by 37

Polymorphic hydroxylation of perhexiline in vitro

Sørensen, L. B., Sørensen, R., Miners, J. O., Somogyi, A. A., Grgurinovich, N., & Birkett, D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01805.x · Cited by 36

The association between antiulcer medication and initiation of cobalamin replacement in older persons

Mitchell, S. L., & Rockwood, K. J. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00340-1 · Cited by 35

Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4

Coller, J. K., Somogyi, A. A., & Bochner, F. (1999) · Xenobiotica · doi:10.1080/004982599238056 · Cited by 35

Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects

Spina, E., Avenoso, A., Campo, G. M., et al. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00539.x · Cited by 35

The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment

Jazwinska-Tarnawska, E. K., Orzechowska-Juzwenko, K., Niewiński, P., Rzemisławska, Z., Loboz-Grudzien, K., Dmochowska-Perz, M., & Sławin, J. (2001) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp39288 · Cited by 35

The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype

WAN, J., XIA, H., He, N., et al. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.42712.x · Cited by 34

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

Lane, H., Hu, O. Y., Jann, M. W., Deng, H.-C., Lin, H.-N., & Chang, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(96)02999-x · Cited by 33

Stereoselective 4′‐hydroxylation of phenytoin: relationship to (S)‐mephenytoin polymorphism in Japanese

Ieiri, I., Mamiya, K., Urae, A., et al. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00572.x · Cited by 33

CYP2C19 pharmacogenetics in the clinical use of proton‐pump inhibitors for gastro‐oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms

Egan, L. J., Myhre, G. M., Mays, D. C., Dierkhising, R., Kammer, P. P., & Murray, J. A. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01645.x · Cited by 33

Identification of Human Cytochrome P-450 Isoforms Involved in Metabolism of R(+)- and S(−)-Gallopamil: Utility of In Vitro Disappearance Rate

Suzuki, A., Iida, I., Tanaka, F., Akimoto, M., Fukushima, K., Tani, M., Ishizaki, T., & Chiba, K. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14926-4 · Cited by 33

Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression

Davidson, J. R. T., McLeod, M. N., & Blum, M. R. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.4.467 · Cited by 33

Risperidone Drug Monitoring

Odou, P., Levron, J. C., Luyckx, M., Brunet, C., & Robert, H. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200019040-00006 · Cited by 32

Polymorphisms and the Pocketbook: The Cost‐Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer

Lehmann, D. F., Medicis, J. J., & Franklin, P. D. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003259389 · Cited by 32

Paroxetine Steady-State Plasma Concentration in Relation to CYP2D6 Genotype in Extensive Metabolizers

Özdemir, V., Tyndale, R. F., Reed, K. L., Herrmann, N., Sellers, E. M., KALOW, W., & Naranjo, C. A. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00014 · Cited by 32

Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. [Erratum to document cited in CA114(15):137136r]

Romkes, M., Faletto, M. B., Blaisdell, J. A., Raucy, J. L., & Goldstein, J. A. (1993) · Biochemistry · doi:10.1021/bi00056a025 · Cited by 31

Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia

Li, K., Li, X., Cheng, Z., Zhang, B., Wen-xing, P., & Huan-de, L. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0853-x · Cited by 31

A comparison of the effects of chlorpromazine, 7-hydroxychlorpromazine and chlorpromazine sulfoxide on the activity of central dopaminergic neurons

Bunney, B. S., & Aghajanian, G. K. (1974) · Life Sciences · doi:10.1016/0024-3205(74)90221-5 · Cited by 28

P-Hydroxylation of Phenobarbital: Relationship to (s)-Mephenytoin Hydroxylation (CYP2C19) Polymorphism

Hadama, A., Ieiri, I., Morita, T., et al. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200104000-00004 · Cited by 27

Pharmacokinetics of Rofecoxib

Davies, N. M., Teng, X. W., & Skjodt, N. M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342060-00004 · Cited by 27

Pharmacokinetics and Pharmacodynamics of the Hydroxy-Metabolite of Glimepiride (Amaryl®) After Intravenous Administration

Badian, M., Korn, A., Lehr, K., et al. (1996) · Drug metabolism and drug interactions · doi:10.1515/dmdi.1996.13.1.69 · Cited by 26

Relationship Between CYP 2D6 Metabolic Status and Sexual Dysfunction in Paroxetine Treatment

Žourková, A., & Žourková, E. H. (2002) · Journal of Sex & Marital Therapy · doi:10.1080/00926230290001565 · Cited by 26

Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy

Capucci, A., Boriani, G., Marchesini, B., Strocchi, E., Tomasi, L., Balducelli, M., Frabetti, L., Ambrosioni, E., & Magnani, B. (1990) · Cardiovascular Drugs and Therapy · doi:10.1007/bf01857646 · Cited by 25

Propafenone in a usual dose produces severe side‐effects: the impact of genetically determined metabolic status on drug therapy

Mörike, K., Magadum, S., Mettang, T., et al. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01225.x · Cited by 25

Does Cocaine Still Have a Role in Nasal Surgery?

Latorre, F., & Klimek, L. (1999) · Drug Safety · doi:10.2165/00002018-199920010-00002 · Cited by 25

Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro

Edstein, M. D., Yeo, A. E. T., Kyle, D. E., et al. (1996) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(96)90531-3 · Cited by 25

CYP2D6*10 Alleles Are Not the Determinant of the Plasma Haloperidol Concentrations in Asian Patients

Shimoda, K., Morita, S., Yokono, A., Someya, T., Hirokane, G., Sunahara, N., & Takahashi, S. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00005 · Cited by 25

The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.

Skjelbo, E., Gram, L. F., & Brøsen, K. (1993) · PubMed · Cited by 24

Overconsumption detected by electronic drug monitoring requires subtle interpretation

Arnet, I. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.103821 · Cited by 23

Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia

Abad, S., Moachon, L., Blanche, P., et al. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01456.x-i2 · Cited by 23

Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes.

Kobayashi, K., Kogo, M., Tani, M., et al. (2001) · PubMed · Cited by 23

Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.

Edstein, M., Shanks, G. D., Teja‐Isavadharm, P., Rieckmann, K., & Webster, H. K. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04241.x · Cited by 22

Effects of Inhaled Corticosteroids, Leukotriene Receptor Antagonists, or Both, Plus Long-Acting ??2-Agonists on Asthma Pathophysiology

Vignola, A. M. (2003) · Drugs · doi:10.2165/00003495-200363002-00004 · Cited by 21

The Role of Cytochrome P450 2C19 Activity in Flunitrazepam Metabolism In Vivo

Gafni, I., Busto, U., Tyndale, R. F., Kaplan, H. L., & Sellers, E. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00009 · Cited by 21

Variability in the elimination of mianserin in elderly patients.

Begg, E., Sharman, J. R., Kidd, J. M., et al. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb05392.x · Cited by 19

Effect of Nortriptyline and Paroxetine on CYP2D6 Activity in Depressed Elderly Patients

Solai, L. K., Pollock, B. G., Mulsant, B. H., Frye, R. F., Miller, M. D., Sweet, R. A., Kirshner, M., Sorisio, D. A., Begley, A. E., & Reynolds, C. F. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200210000-00007 · Cited by 19

Time‐Dependent Amplified Pharmacokinetic and Pharmacodynamic Responses of Rabeprazole in Cytochrome P450 2C19 Poor Metabolizers

Lin, C., Yang, J., Uang, Y., Chern, H., & Wang, T. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.6.711.32177 · Cited by 18

Polymorphic oxidative metabolism of proguanil in a Nigerian population

Bolaji, O., Sadare, I., Babalola, C. P., & Ogunbona, F. A. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0509-7 · Cited by 18

Ticlopidine inhibits phenytoin clearance

DONAHUE, S., FLOCKHART, D., & ABERNETHY, D. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.103277001 · Cited by 17

Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism

Lutz, M., Schwab, M. G., Griese, E., Marx, C., Müller-Oerlinghausen, B., Schönhöfer, P. S., Meisner, C., Gleiter, C. H., Eichelbaum, M. F., & Mörike, K. (2002) · Pharmacogenetics · doi:10.1097/00008571-200201000-00010 · Cited by 15

Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians

Dalen, P. A. V., Dahl, M.-L., Hk, R., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01804.x · Cited by 15

Lumiracoxib: Pharmacokinetic and Pharmacodynamic Profile When Coadministered with Fluconazole in Healthy Subjects

Scott, G., Yih, L., Yeh, C., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262110 · Cited by 15

Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms

Rafii, A., McGrath, S. D., Blinder, M. A., Buchman, T. G., Zehnbauer, B. A., & Freeman, B. D. (2001) · American Journal of Hematology · doi:10.1002/ajh.1094 · Cited by 15

Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations.

Tacke, U., Leinonen, E. V. J., Lillsunde, P. M., Seppälä, T. T., Arvela, P. I., Pelkonen, O., & Ylitalo, P. (1992) · PubMed · Cited by 15

Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.

Schellens, J. H. M., van der Wart, J., & Breimer, D. D. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03687.x · Cited by 14

Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1–5 for gastric cancer, and its pharmacologic and kinetic rationale

Terashima, M., Irinoda, T., Kawamura, H., Takagane, A., Abe, K., Oyama, K., Fujiwara, H., Saito, K., Gotoh, M., & Shirasaka, T. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0568-1 · Cited by 11

Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.

Rahav, G., Zylber‐Katz, E., Rachmilewitz, D., & Levy, M. (1990) · PubMed · Cited by 10

Cancer pharmacogenomics: achievements in basic research

Nakajima, M., & Yokoi, T. (2005) · International Journal of Clinical Oncology · doi:10.1007/s10147-004-0463-8 · Cited by 7

Acetylator status and inhibition of platelet monoamine oxidase following treatment with pheneizine

Yates, C. M., & Loudon, J. B. (1979) · Psychological Medicine · doi:10.1017/s0033291700034127 · Cited by 7

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593

Pharmacokinetics

Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309

Sex-specific differences in CYP450 isoforms in humans

Scandlyn, M. J., Stuart, E. C., & Rosengren, R. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.413 · Cited by 199

Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review

Zobdeh, F., Eremenko, I. I., Akan, M. A., Tarasov, V. V., Chubarev, V. N., Schiöth, H. B., & Mwinyi, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061190 · Cited by 45

Integument

Diegel, K. L., Danilenko, D. M., & Wojcinski, Z. W. (2013) · Haschek and Rousseaux's Handbook of Toxicologic Pathology · doi:10.1016/b978-0-12-415759-0.00055-8 · Cited by 6